UNSPSC 51101936: Sitamaquine

This classification denotes an antiprotozoal agent with the molecular formula C21H33N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AIJ4TGC6B, chemically known as 1,6-hexanediamine, n,n-diethyl-n-(6-methoxy-4-methyl-8-quinolinyl)- but generally known as sitamaquine, which bears US NIH Compound Identifier 42548. European Medicines Agency schedules Sitamaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37607.

UNSPSC 51101936 Sitamaquine, a Commodity code, shows activity misaligned with its nominal scope: recent state and local opportunities tagged under this code are actually soliciting naloxone kits, first-aid and rescue supplies, generic pharmaceuticals, and over-the-counter products — none of which are sitamaquine, an antimalarial pharmaceutical. The code's abstract definition does not match what is actually being purchased in the current solicitation window, suggesting either a cataloging error in the source data or a fundamental mismatch between code assignment and procurement intent.

Recent opportunities span health departments, fire departments, and cooperative purchasing alliances across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives. The City of Tampa issued an IFB (26P00145, due March 13, 2026) for 169 line items of medical and first-aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5% Small Local Business Enterprise discount set-aside of up to $10,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, with contract effectiveness targeted for July 1, 2026 and a 3 percent administrative fee required of vendors. Because the recent opportunities are substantively unrelated to sitamaquine itself, this code presents limited strategic relevance for vendors focused on antimalarial procurement.